Table 1.
Baseline characteristics of patients with advanced UC treated with first line ICI included in risk score modeling
| First line ICI | |
|---|---|
| N=357 | |
| Age (year), mean (range) | 71 (32–93) |
| Sex, n (%) | |
| Male | 259 (73) |
| Female | 98 (27) |
| Race/Ethnicity, n (%) | |
| Caucasian/White | 263 (74) |
| Hispanic/Latino | 43 (12) |
| Black/African-American | 20 (6) |
| Asian | 13 (4) |
| Other/Unknown | 18 (5) |
| Smoking History, n (%) | |
| Yes | 243 (68) |
| No | 111 (31) |
| Unknown | 3 (1) |
| Continent of treatment, n (%) | |
| North America (US only) | 91 (25) |
| Europe | 266 (75) |
| Site of Primary Disease, n (%) | |
| Bladder | 296 (83) |
| Upper tract (renal pelvis or ureter) | 48 (13) |
| Urethra | 3 (1) |
| Unknown | 10 (3) |
| Histology, n (%) | |
| Pure UC | 242 (68) |
| UC with variant histology | 115 (32) |
| History of extirpative surgery, n (%) | |
| Yes | 184 (52) |
| No | 148 (41) |
| Unknown | 25 (7) |
| History of BCG, n (%) | |
| Yes | 74 (21) |
| No | 278 (78) |
| Unknown | 5 (1) |
| Prior platinum chemotherapy, n (%) | |
| Yes | 147 (41) |
| No | 210 (59) |
| Agent received, n (%) | |
| Atezolizumab | 137 (38) |
| Avelumab | 1 (0.1) |
| Durvalumab | 11 (3) |
| Nivolumab | 16 (4) |
| Pembrolizumab | 189 (53) |
| Unknown | 3 (1) |
| GFR<60ml/min at ICI start, n (%) | |
| Yes | 137 (38) |
| No | 191 (54) |
| Unknown | 29 (8) |
| Metastatic disease site at ICI start, n (%) | |
| Bone | 81 (23) |
| Liver | 58 (16) |
| Lung | 107 (30) |
| Lymph node | 243 (68) |
| ECOG Performance Status, n (%) | |
| 0 | 80 (22) |
| 1 | 176 (49) |
| 2 | 90 (25) |
| 3 | 9 (3) |
| 4 | 2 (1) |
| Median (IQR) | |
| Albumin at ICI start (g/dL) | 3.8 (3.4–4.1) |
| Hemoglobin at ICI start (mg/dL) | 11.6 (10.0–13.1) |
| ALC at ICI start (x10^3/ul) | 1.3 (0.9–1.8) |
| ANC at ICI start (x10^3/ul) | 5.5 (4.1–7.3) |
| NLR at ICI start | 4.2 (2.7–7.1) |
| Platelets at ICI start (x10^9/L) | 254 (201–334) |
Abbreviations: ALC indicates absolute lymphocyte count; ANC, absolute neutrophil count; BCG, Bacillus Calmette-Guérin; ECOG, Eastern Cooperative Oncology Group; GFR, glomerular filtration rate; ICI, immune checkpoint inhibitor; IQR, inter-quartile range; LDH, lactate dehydrogenase; NLR, neutrophil : lymphocyte ratio; PS, performance status; SD, standard deviation; UC, urothelial carcinoma.